ME02845B - ASIMETRIČNE UREE l NJIHOVE MEDICINSKE UPOTREBE - Google Patents

ASIMETRIČNE UREE l NJIHOVE MEDICINSKE UPOTREBE

Info

Publication number
ME02845B
ME02845B MEP-2017-123A MEP2017123A ME02845B ME 02845 B ME02845 B ME 02845B ME P2017123 A MEP2017123 A ME P2017123A ME 02845 B ME02845 B ME 02845B
Authority
ME
Montenegro
Prior art keywords
ethyl
urea
methylpiperidin
methyl
dichlorophenyl
Prior art date
Application number
MEP-2017-123A
Other languages
English (en)
French (fr)
Inventor
Claudio Pietra
Claudio Giuliano
Rubio Silvina Garcia
Zhigang Li
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of ME02845B publication Critical patent/ME02845B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Claims (22)

1. Jedinjenje formule (I) ili njegova farmaceutski prihvatljiva so ili adukt, u kome: R je aril izborno supstituisan sa jednim ili više nezavisnih R103 supstituenata; R1 je izabran iz grupe koja se sastoji od hidroksialkila, alkila, izborno supstitusanog sa jednim ili više nezavisnih R103 supstituenata; R4 je izabran iz grupe koja se sastoji od alkila, arila, arilalkila, izborno supstituisanog sa jednim ili više nezavisnih R103 supstituenata; ili R4 je OR103; R6, R7, R8, R9 su izabrani iz grupe koja se sastoji od vodonika i alkila; R103 je izabran iz grupe koja se sastoji od vodonika, cijano, -NO2, -OR104, hidroksi, amino, alkil, alkenil, cikloalkil, halogen, alkoksi, alkoksialkil, aril, arilalkil, heterocikloalkil, heterocikloalkilalkil, heteroaril, heteroarilalkil, -C(O)R104 -C(O)OR104 -C(O)NR104R105, -NR104R105, -NR104S(O)2R105,-NR104C(O)R105, -S(O)2R104 , -SR104 i -S(O)2NR104R105, svaki izborno nezavisno supstituisan sa jednim ili više nezavisnih R103 supstituenata; i R104 i R105 su svaki nezavisno izabrani iz grupe koja se sastoji od vodonika, cijano, NO2, hidroksi, hidroksialkil, amino, alkil, alkenil, cikloalkil, halogen, alkoksi, alkoksialkil, aril, arilalkil, heterocikloalkil, heterocikloalkilalkil, heteroaril i heteroarilalkil.
2. Jedinjenje prema patentnom zahtevu 1, naznačeno time što R je izabran iz grupe koja se sastoji od fenila, naftalena, tetrahidronaftalenila, indenila, izoindenila, indanila, antracenila, fenantrenila, benzonaftenil, fluorenila, pri čemu je navedeni R izborno supstituisan sa jednim ili više nezavisnih R103 supstituenata.
3. Jedinjenje prema patentnom zahtevu 1, naznačeno time što R je fenil ili naftalen koji je izborno nezavisno supstituisan sa od jednog do šest supstituenata nezavisno izabranih iz grupe koja se sastoji od hloro, fluoro, bromo, metoksi i etoksi.
4. Jedinjenje prema patentnom zahtevu 1, naznačeno time što R1 je izabran iz grupe koja se sastoji od metila, -CH2OH i -CH2-OCH2-fenila.
5. Jedinjenje prema patentnom zahtevu 1, naznačeno time što R4 je metil, etil, benzil ili benzil supstituisan sa od jednog do pet supstituenata nezavisno izabranih iz grupe koja se sastoji od metil, fluoro, hloro, trifluorometil, metoksi, cijano i hidroksi.
6. Jedinjenje prema patentnom zahtevu 1, naznačeno time što su svaki R8 i R9 nezavisno vodonik, metil ili etil.
7. Jedinjenje prema patentnom zahtevu 1: Jedinjenje br. Hemijska struktura Hemijski naziv GA1 1-metil-3-((R)-1-(naftalen-1- il)etil)-1-(1,3,3- trimetilpiperidin-4-il)urea, GA2 1-metil-3-((S)-1-(naftalen-1- il)etil)-1-(1,3,3- trimetilpiperidin-4-il)urea, GA3 1-metil-3-(1-(naftalen-1- il)etil)-1-(1,3,3- trimetilpiperidin-4-il)urea, GA4 3-(1-(4-metoksinaftalen-1- il)etil)-1-metil-1-(1,3,3- trimetilpiperidin-4-il)urea, GA5 1-benzil-3-((R)-1-(naftalen-1- il)etil)-1-(1,3,3- trimetilpiperidin-4-il)urea, GA6 3-(1-(2,3-dihlorofenil)etil)-1- (3-metoksibenzil)-1-(1,3,3- trimetilpiperidin-4-il)urea, GA7 3-(1-(2,3-dihlorofenil)etil)-1- (2-fluorobenzil)-1-(1,3,3- trimetilpiperidin-4-il)urea, GA8 3-(1-(2,3-dihloro-4- metoksifenil)etil)-1-metil-1- (1,3,3-trimetilpiperidin-4-il)urea, GA9 3-(1-(2,3-dihlorofenil)etil)-1- metil-1-(1,3,3-trimetilpiperidin- 4-il)urea, GA10 3-((R)-1-(2,3-dihloro-4- metoksifenil)etil)-1-(1,3- dimetilpiperidin-4-il)-1-(3- metoksibenzil)urea, GA11 1-benzil-3-(1-(2,3- dihlorofenil)propil)-1-(1,3,3- trimetilpiperidin-4-il)urea, GA12 3-((S)-1-(2,3- dihlorofenil)etil)-1-metil-1- (1,3,3-trimetilpiperidin-4-il)urea, GA13 3-((R)-1-(2,3- dihlorofenil)etil)-1-metil-1- (1,3,3-trimetilpiperidin-4-il)urea, GA14 3-(1-(2,3-dihlorofenil)etil)-1- metil-1-(1,3,3-trimetilpiperidin- 4-il)urea, GA15 1-benzil-3-((S)-1-(naftalen-1- il)etil)-1-(1,3,3- trimetilpiperidin-4-il)urea, GA16 1-benzil-3-((R)-1-(naftalen-1- il)etil)-1-(1,3,3- trimetilpiperidin-4-il)urea, GA17 1-benzil-3-(1-(naphthalcn-1- il)etil)-1-(1,3,3- trimetilpiperidin-4-il)urea, GA18 3-(1-(2,3-dihlorofenil)propil)- 1-metil-1-(1,3,3- trimetilpiperidin-4-il)urea, GA19 3-(1-(2,3-difluorofenil)etil)-1- metil-1-(1,3,3-trimetilpiperidin- 4-il)urea, GA20 1-benzil-3-(1-(2,3- dihlorofenil)etil)-1-(1,3,3- trimetilpiperidin-4-il)urea, GA21 1-benzil-3-(1-(2,3- difluorofenil)etil)-1-(1,3,3- trimetilpiperidin-4-il)urea, GA22 1-benzil-3-(1-(4- metoksinaftalen-1-il)etil)-1- (1,3,3-trimetilpiperidin-4-il)urea, GA23 3-(1-(2,3-dihloro-4- metoksifenil)etil)-1-metil-1- (l,3,3-trimetilpiperidin-4-il)urea, GA24 3-(1-(2,3-dihlorofenil)etil)-1- metil-1-(1,2,2,5,5- pentametilpiperidin-4-il)urea, GA26 3-(2-hidroksi-1-(naftalen-1- il)etil)-1-metil-1-(1,3,3- trimetilpiperidin-4-il)urea, GA27 1-(4-hlorobenzil)-3-(1-(2,3- dihlorofenil)etil)-1-(1,3,3- trimetilpiperidin-4-il)urea, GA28 1-benzil-1-(3,3-dietil-1- metilpiperidin-4-il)-3-((S)-1- (naftalen-1-il)etil)urea, GA29 1-benzil-1-(3,3-dietil-1- metilpiperidin-4-il)-3-((R)-1- (naftalen-1-il)etil)urea, GA30 1-benzil-1-(3,3-dietil-1- metilpiperidin-4-il)-3-(1- (naftalen-1-il)etil)urea, GA31 3-(2-(benziloksi)-1-(naftalen-1- il)etil)-1-metil-1-(1,3,3- trimetilpiperidin-4-il)urea, GA33 3-((R)-1-(2,3- dihlorofenil)etil)-1-(3- metoksibenzil)-1-(1,3,3- trimetilpiperidin-4-il)urea, GA34 3-(2-ciklopropil-1-(2,3- dihlorofenil)etil)-1-(3- metoksibenzil)-1-(1,3,3- trimetilpiperidin-4-il)urea, GA35 3-(1-(2,3-dihlorofenil)etil)-1- (3-hidroksibenzil)-1-(1,3,3- trimetilpiperidin-4-il)urea, GA37 1-benzil-3-(1-(2,3- dihidroksifenil)etil)-1-(1,3,3- trimetilpiperidin-4-il)urea, GA38 3-((R)-1-(2,3- dihlorofenil)etil)-1-(3-(2- hidroksietoksi)benzil)-1-(1,3,3- trimetilpiperidin-4-il)urea, GA39 3-(1-(2,3-difluoro-4- metoksifenil)etil)-1-metil-1- (1,3,3-trimetilpiperidin-4-il)urea, GA40 3-(1-(2,3-difluoro-4- hidroksifenil)etil)-1-metil-1- (1,3,3-trimetilpiperidin-4-il)urea, GA44 4-(3-(1-(2,3-dihlorofenil)etil)- 1-metilureido)-1,3,3- trimetilpiperidin 1-oksid, GA46 1-etil-1-(1-metilpiperidin-4-il)- 3-(1-(naftalen-1-il)etil)urea, GA47 3-(1-(4-metoksinaftalen-1- il)etil)-1-metil- metilpiperidin-4-il)urea, GA48 3-(2-hidroksi-1-(naftalen-1- il)etil)-1-metil-1-(1- metilpiperidin-4-il)urea, GA49 3-(2-hidroksi-1-(4- metoksinaftalen-1-il)etil)-1- metil-1-(1-metilpiperidin-4- il)urea, GA50 1-(1-metilpiperidin-4-il)-3-(1- (naftalen-1-il)etil)-1-(piridin- 3-ilmetil)urea, GA57 1-(cikloheksilmetil)-1-(1- metilpiperidin-4-il)-3-(1- (naftalen-1-il)etil)urea, GA58 1-izopropil-1-(1-metilpiperidin- 4-il)-3-(1-(naftalen-1- il)etil)urea, GA59 1-(2-metoksietil)-1-(1- metilpiperidin-4-il)-3-(1- (naftalen-1-il)etil)urea, GA62 1-(ciklopropilmetil)-1-(1- metilpiperidin-4-il)-3-(1- (naftalen-1-il)etil)urea, GA63 3-(1-(2-metoksinaftalen-1- il)etil)-1-metil-1-(1- metilpiperidin-4-il)urea, GA67 3-(2-metoksi-1-(naftalen-1- il)etil)-1-metil- metilpiperidin-4-il)urea, GA68 3-(3-metoksi-1-(naftalen-1- il)propil)-1-metil-1-(1- metilpiperidin-4-il)urea, GA69 1-metil-1-(1-metilpiperidin-4- il)-3-(1-(naftalen-1- il)propil)urea, GA73 (S)-1-(1-metilpiperidin-4-il)-3- (1-(naftalen-1-il)etil)-1- (piridin-3-ilmetil)urea, GA74 (R)-1-(1-metilpiperidin-4-il)-3- (1-(naftalen-1-il)etil)-1- (piridin-3-ilmetil)urea, GA75 1-izobutil-1-(1-metilpiperidin-4- il)-3-(1-(naftalen-1- il)etil)urea, GA76 1-(ciklobutilmetil)-1-(1- metilpiperidin-4-il)-3-(1- (naftalen-1-il)etil)urea, GA77 1-butil-1-(1-metilpiperidin-4-il)- 3-(1-(naftalen-1-il)etil)urea, GA79 1-(1-metilpiperidin-4-il)-3-(1- (naftalen-1-il)etil)-1-(piridin- 2-ilmetil)urea, GA80 1-(1-metilpiperidin-4-il)-3-(1- (naftalen-1-il)etil)-1-(piridin- 4-ilmetil)urea, GA82 (R)-1-etil-1-(1-metilpiperidin- 4-il)-3-(1-(naftalen-1- il)etil)urea, GA83 3-(2-hidroksi-1-(4- metoksinaftalen-1-il)etil)-1- metil-1-(1-metilpiperidin-4- il)urea, GA84 3-(2-hidroksi-1-(naftalen-1- il)etil)-1-(1-metilpiperidin-4- il)-1-(piridin-3-ilmetil)urea, GA85 3-(2-metoksi-1-(4- metoksinaftalen-1-il)etil)-1- metil-1-(1-metilpiperidin-4- il)urea, GA86 3-(1-(2,3-dihlorofenil)etil)-1- (3-hidroksibenzil)-1-(1- metilpiperidin-4-il)urea, GA87 1-benzil-1-(1,3-dimetilpiperidin- 4-il)-3-((R)-1-(naftalen-1- il)etil)urea, GA88 1-(1,3-dimetilpiperidin-4-il)-1- metil-3-((R)-1-(naftalen-1- il)etil)urea, GA89 3-(1-(4-metoksinaftalen-1- il)etil)-1-metil-1-(1- metilpiperidin-4-il)urea, GA90 (R)-3-(1-(4-metoksinaftalen-1- il)etil)-1-metil-1-(1- metilpiperidin-4-il)urea, GA91 (S)-3-(1-(4-metoksinaftalen-1- il)etil)-1-metil-1-(1- metilpiperidin-4-il)urea, GA92 3-(1-(4,8-dimetoksinaftalen-1- il)etil)-1-metil- metilpiperidin-4-il)urea, GA93 3-(1-(4- (metoksimetoksi)naftalen-1- il)etil)-1-metil-1-(1- metilpiperidin-4-il)urea, GA94 3-(2-(benziloksi)-1-(2,3- dihlorofenil)etil)-1-metil-1- (1-metilpiperidin-4-il)urea, GA95 (R)-3-(2-(benziloksi)-1-(2,3- dihlorofenil)etil)-1-metil-1- (1-metilpiperidin-4-il)urea, GA96 (S)-3-(2-(benziloksi)-1-(2,3- dihlorofenil)etil)-1-metil-1- (1-metilpiperidin-4-il)urea, GA97 3-(1-(2,3-dihlorofenil)etil)-1- metil-1-(1-metilpiperidin-4- il)urea, GA98 1-benzil-3-(1-(2,3- dihlorofenil)etil)-1-(1- metilpiperidin-4-il)urea, GA99 3-(1-(2,3-dihlorofenil)etil)-1- (3-fluorobenzil)-1-(1- metilpiperidin-4-il)urea, GA100 1-(2-hlorobenzil)-3-(1-(2,3- dihlorofenil)etil)-1-(1- metilpiperidin-4-il)urea, GA101 3-(1-(3,5-difluorofenil)etil)-1- metil-1-(1-metilpiperidin-4- il)urea, GA102 3-(1-(2-hlorofenil)etil)-1- metil-1-(1-metilpiperidin-4- il)urea, GA103 3-(1-(3-fluorofenil)etil)-1- metil-1-(1-metilpiperidin-4- il)urea, GA104 3-(1-(4-hlorofenil)etil)-1- metil-1-(1-metilpiperidin-4- il)urea, GA105 3-(1-(2,4-difluorofenil)etil)-1- metil-1-(1-metilpiperidin-4- il)urea, GA106 1-metil-1-(1-metilpiperidin-4- il)-3-(1-(o-tolil)etil)urea, GA107 1-metil-1-(1-metilpiperidin-4- il)-3-(1-(4-(metilsulfonil)fenil)etil)urea, GA108 1-(cikloheksilmetil)-3-(1-(2,3- dihlorofenil)etil)-1-(1- metilpiperidin-4-il)urea, GA109 1-(ciklopropilmetil)-3-(1-(2,3- dihlorofenil)etil)-1-(1- metilpiperidin-4-il)urea, GA110 3-(1-(2,3-dihlorofenil)etil)-1- etil-1-(1-metilpiperidin-4- il)urea, GA111 3-(1-(2,3-dihlorofenil)etil)-1- (1-metilpiperidin-4-il)-1- (piridin-3-ilmetil)urea, GA112 3-(1-(3-hlorofenil)etil)-1- metil-1-(1-metilpiperidin-4- il)urea, GA113 1-benzil-3-(1-(3- hlorofenil)etil)-1-(1- metilpiperidin-4-il)urea, GA114 1-(3-hlorobenzil)-3-(1-(2,3- dihlorofenil)etil)-1-(1- metilpiperidin-4-il)urea, GA115 3-(1-(2,3-dihlorofenil)etil)-1- (2-metoksibenzil)-1-(1- metilpiperidin-4-il)urea, GA116 3-(1-(2,3-dihlorofenil)etil)-1- (3-metoksibenzil)-1-(1- metilpiperidin-4-il)urea, GA117 3-(1-(2,3-dihlorofenil)etil)-1- (4-fluorobenzil)-1-(1- metilpiperidin-4-il)urea, GA118 3-(1-(2,3-dihlorofenil)etil)-1- (2-fluorobenzil)-1-(1- metilpiperidin-4-il)urea, GA119 1-(4-hlorobenzil)-3-(1-(2,3- dihlorofenil)etil)-1-(1- metilpiperidin-4-il)urea, GA120 3-(1-(3,4-dihlorofenil)etil)-1- metil-1-(1-metilpiperidin-4- il)urea, GA121 3-(1-(2,3-dihlorofenil)etil)-1- (4-metoksibenzil)-1-(1- metilpiperidin-4-il)urea, GA122 3-(1-(2,3-dihlorofenil)propil)- 1-etil-1-(1-metilpiperidin-4- il)urea, GA123 1-(cikloheksilmetil)-3-(1-(2,3- dihlorofenil)propil)-1-(1- metilpiperidin-4-il)urea, GA124 3-(1-(2,3-difluorofenil)etil)-1- metil-1-(1-metilpiperidin-4- il)urea, GA125 1-benzil-3-(1-(2,3- difluorofenil)etil)-1-(1- metilpiperidin-4-il)urea, GA126 1-(cikloheksilmetil)-3-(1-(2,3- difluorofenil)etil)-1-(1- metilpiperidin-4-il)urea, GA127 (R)-3-(1-(2,3- dihlorofenil)etil)-1-etil-1-(1- metilpiperidin-4-il)urea, GA128 1-benzil-3-(1-(2,3- dihlorofenil)etil)-1-(1,3- dimetilpiperidin-4-il)urea, GA129 3-(1-(2,3-dihlorofenil)etil)-1- (1,3-dimetilpiperidin-4-il)-1- metilurea, GA130 (S)-3-(1-(2,3- dihlorofenil)etil)-1-etil-1-(1- metilpiperidin-4-il)urea, GA131 (R)-3-(1-(2,3- dihlorofenil)etil)-1-etil-1-(1- metilpiperidin-4-il)urea, GA132 3-(1-(2,3-dihlorofenil)etil)-1- etil-1-(1-metilpiperidin-4- il)urea, GA133 3-((R)-1-(2,3-dihloro-4- metoksifenil)etil)-1-(1,3- dimetilpiperidin-4-il)-1-(3- metoksibenzil)urea, GA134 3-((S)-1-(2,3-dihloro-4- metoksifenil)etil)-1-(1,3- dimetilpiperidin-4-il)-1-(3- metoksibenzil)urea, GA135 3-(1-(2,3-dihloro-4- metoksifenil)etil)-1-(1,3- dimetilpiperidin-4-il)-1-(3- metoksibenzil)urea, GA136 3-(1-(2,3-difluorofenil)etil)-1- (1,3-dimetilpiperidin-4-il)-1-(3- metoksibenzil)urea, GA137 3-(1-(2,3-dihlorofenil)etil)-1- (4-(hidroksimetil)benzil)-1-(1- metilpiperidin-4-il)urea, GA138 metil 4-((3-(1-(2,3- dihlorofenil)etil)-1-(1- metilpiperidin-4- il)ureido)metil)benzoat, GA139 3-(2-ciklopropil-1-(2,3- dihlorofenil)etil)-1-metil-1- (1-metilpiperidin-4-il)urea, GA140 3-(1-(2,3-dihlorofenil)-2- hidroksietil)-1-metil-1-(1- metilpiperidin-4-il)urea, GA141 (R)-1-(2-hlorobenzil)-3-(1-(2,3- dihlorofenil)etil)-1-(1- metilpiperidin-4-il)urea, GA142 (S)-1-(2-hlorobenzil)-3-(1-(2,3- dihlorofenil)etil)-1-(1- metilpiperidin-4-il)urea, GA143 1-(2-hlorobenzil)-3-(1-(2,3- dihlorofenil)etil)-1-(1- metilpiperidin-4-il)urea, GA144 3-(1-(2,3-dimetoksifenil)etil)- 1-metil-1-(1-metilpiperidin-4- il)urea, GA145 3-(1-(2,3-difluoro-4- metoksifenil)etil)-1-metil-1- (1-metilpiperidin-4-il)urea, GA146 3-(1-(2,3-dihlorofenil)-2- metoksietil)-1-metil-1-(1- metilpiperidin-4-il)urea, GA147 N-(2,3-dihloro-4-(1-(3-metil-3- (1-metilpiperidin-4- il)ureido)etil)fenil)acetamid, GA148 3-(1-(4-amino-2,3- dihlorofenil)etil)-1-metil-1- (1-metilpiperidin-4-il)urea, GA149 3-(1-(2,3-dihloro-4- metoksifenil)etil)-1-metil-1- (1-metilpiperidin-4-il)urea, GA150 1-etil-1-(1-metilpiperidin-4-il)- 3-(1-(naftalen-1-il)-3-(3- (piridin-3- iloksi)fenil)propil)urea, GA151 1-metil-1-(1-metilpiperidin-4- il)-3-(1-(naftalen-1-il)-3- (piridin-3-il)propil)urea, GA152 1-metil-1-(1-metilpiperidin-4- il)-3-(3-morpholino-1-(naftalen- 1-il)propil)urea, GA153 1-etil-3-(3-(3-metoksifenil)-1- (naftalen-1-il)propil)-1-(1- metilpiperidin-4-il)urea, GA154 3-(3-(3-(benziloksi)fenil)-1- (naftalen-1-il)propil)-1-etil-1- (1-metilpiperidin-4-il)urea, GA155 1-etil-1-(1-metilpiperidin-4-il)- 3-(1-(naftalen-1-il)-3-(piridin- 3-il)propil)urea, GA156 3-(3-(3-(benziloksi)fenil)-1- (naftalen-1-il)propil)-1-(1- metilpiperidin-4-il)-1-(piridin-3- ilmetil)urea, GA157 3-(3-(3-(benziloksi)fenil)-1-(2,3- dihlorofenil)propil)-1-metil- 1-(1-metilpiperidin-4-il)urea, GA158 3-(2-(benziloksi)-1-(2,3- dihlorofenil)etil)-1-metil-1- (1-metilpiperidin-4-il)urea, GA159 3-(2-(benzilamino)-1-(2,3- dihlorofenil)etil)-1-metil-1- (1-metilpiperidin-4-il)urea, GA160 3-(1-(2,3-dihlorofenil)-2-((3- (hidroksimetil)benzil)oksi)etil)- 1-metil-1-(1-metilpiperidin-4- il)urea, GA161 3-(2-(benziloksi)-1-(2,3- dihlorofenil)etil)-1-(2- hlorobenzil)-1-(1- metilpiperidin-4-il)urea, GA162 3-(2-(benziloksi)-1-(2,3- dihlorofenil)etil)-1-(4- (hidroksimetil)benzil)-1-(1- metilpiperidin-4-il)urea, GA163 3-(1-(2,3-dihlorofenil)-2-((4- metoksibenzil)oksi)etil)-1- metil-1-(1-metilpiperidin-4- il)urea, GA164 3-(1-(2,3-dihlorofenil)-2- (piridin-4-ilmetoksi)etil)-1- metil-1-(1-metilpiperidin-4- il)urea, GA165 3-(1-(2,3-dihloro-4- metoksifenil)etil)-1-metoksi- 1-(1-metilpiperidin-4-il)urea, GA166 (S)-3-(1-(2,3-dihloro-4- metoksifenil)etil)-1-metoksi- 1-(1-metilpiperidin-4-il)urea, GA167 (R)-3-(1-(2,3-dihloro-4- metoksifenil)etil)-1-metoksi- 1-(1-metilpiperidin-4-il)urea, GA168 1-hidroksi-3-(1-(4- metoksinaftalen-1-il)etil)-1- (1-metilpiperidin-4-il)urea, GA169 (R)-1-hidroksi-3-(1-(4- metoksinaftalen-1-il)etil)-1- (1-metilpiperidin-4-il)urea, GA170 (S)-1-hidroksi-3-(1-(4- metoksinaftalen-1-il)etil)-1- (1-metilpiperidin-4-il)urea, GA171 3-(1-(2,3-dihlorofenil)etil)-1- metoksi-1-(1-metilpiperidin-4- il)urea, GA172 (R)-3-(1-(2,3- dihlorofenil)etil)-1-metoksi- 1-(1-metilpiperidin-4-il)urea, GA173 (S)-3-(1-(2,3- dihlorofenil)etil)-1-metoksi- 1-(1-metilpiperidin-4-il)urea, GA174 1-metoksi-3-(1-(4- metoksinaftalen-1-il)etil)-1- (1-metilpiperidin-4-il)urea, GA175 (R)-1-metoksi-3-(1-(4- metoksinaftalen-1-il)etil)-1- (1-metilpiperidin-4-il)urea, GA176 (S)-1-metoksi-3-(1-(4- metoksinaftalen-1-il)etil)-1- (1-metilpiperidin-4-il)urea, GA177 3-(1-(2,3-dihlorofenil)etil)-1- hidroksi-1-(1-metilpiperidin-4- il)urea, GA178 (R)-3-(1-(2,3- dihlorofenil)etil)-1-hidroksi-1- (1-metilpiperidin-4-il)urea, GA179 (S)-3-(1-(2,3- dihlorofenil)etil)-1-hidroksi-1- (1-metilpiperidin-4-il)urea, GA180 3-(1-(2,3-dihloro-4- metoksifenil)etil)-1-hidroksi- 1-(1-metilpiperidin-4-il)urea, G181 (R)-3-(1-(2,3-dihloro-4- metoksifenil)etil)-1-hidroksi- 1-(1-metilpiperidin-4-il)urea, GA182 (S)-3-(1-(2,3-dihloro-4- metoksifenil)etil)-1-hidroksi- 1-(1-metilpiperidin-4-il)urea, GA183 3-(1-(2,3-dihloro-4- (dimetilamino)fenil)etil)-1- metil-1-(1-metilpiperidin-4- il)urea, GA184 3-(1-(4-((4- metoksibenzil)oksi)naftalen-1- il)etil)-1-metil-1-(1- metilpiperidin-4-il)urea, G185 3-(1-(4-hidroksinaftalen-1- il)etil)-1-metil-1-(1- metilpiperidin-4-il)urea, GA186 3-(1-(4,5-dimetoksinaftalen-1- il)etil)-1-metil-1-(1- metilpiperidin-4-il)urea, GA187 3-(1-(2,3-dihlorofenil)-2- (piridin-3-ilmetoksi)etil)-1- metil-1-(1-metilpiperidin-4- il)urea, GA189 3-(1-(2-hloro-3,4- dimetoksifenil)etil)-1-metil- 1-(1-metilpiperidin-4-il)urea, GA190 1-metil-1-(1-metilpiperidin-4- il)-3-(1-(2,3,4- trihlorofenil)etil)urea, GA191 1-metil-1-(1-metilpiperidin-4- il)-3-(1-(4-(piridin-4- ilmetoksi)naftalen-1- il)etil)urea, GA192 3-(1-(6-hloro-[1,1′-bifenil]-2- il)etil)-1-metil-1-(1- metilpiperidin-4-il)urea, GA193 3-(1-(3-hloro-2-(piridin-4- il)fenil)etil)-1-metil-1-(1- metilpiperidin-4-il)urea, GA194 3-(1-(2,3-dihloro-4- metilfenil)etil)-1-metil-1- (1-metilpiperidin-4-il)urea, GA195 3-(1-(3-hloro-2- metilfenil)etil)-1-metil-1- (1-metilpiperidin-4-il)urea, GA196 3-(1-(2,3-dihlorofenil)-2-((4- (hidroksimetil)benzil)oksi)etil)- 1-metil-1-(1-metilpiperidin-4- il)urea, GA197 3-(1-(2,3-dihloro-4- metoksifenil)etil)-1-metil-1- (1-metilpiperidin-4-il)urea, GA198 (R)-3-(1-(2,3-dihloro-4- metoksifenil)etil)-1-metil-1- (1-metilpiperidin-4-il)urea, GA199 (S)-3-(1-(2,3-dihloro-4- metoksifenil)etil)-1-metil-1- (1-metilpiperidin-4-il)urea, GA200 3-(1-(2,3-dihloro-4- metoksifenil)etil)-1-metil-1- (1,3,3-trimetilpiperidin-4-il)urea, GA201 3-((R)-1-(2,3-dihloro-4- metoksifenil)etil)-1-metil-1- (1,3,3-trimetilpiperidin-4-il)urea, GA202 3-((S)-1-(2,3-dihloro-4- metoksifenil)etil)-1-metil-1- (1,3,3-trimetilpiperidin-4-il)urea, i GA203 3-(1-(4-(2- (benziloksi)etoksi)naftalen-1- il)etil)-1-metil-1-(1- metilpiperidin-4-il)urea.
8. Jedinjenje formule (I) prema bilo kom od patentnih zahteva 1- 7, ili njegova farmaceutski prihvatljiva so ili adukt za upotrebu u postupku za prevenciju i/ili lečenje subjekta koji ima bolest koja je patofiziološki posredovana preko receptora za grelin, pri čemu je navedena bolest izabrana od gojaznosti, prekomerne težine, poremećaja ishrane, dijabetesa, metaboličkog sindroma, metaboličkog poremećaja, kaheksije koja je rezultat kancera, kongestivne srčane insuficijencije, smanjenja telesne težine kao posledice starenja ili SIDA-e, hronične insuficijencije jetre, hronične opstruktivne bolesti pluća, gastrointestinalne bolesti, poremećaja želudca ili zloupotrebe supstanci.
9. Jedinjenje za upotrebu prema patentnom zahtevu 8, naznačeno time što navedeni metabolički poremećaj je izabran iz grupe koja se sastoji od dijabetesa, dijabetesa tipa I, dijabetesa tipa II, neodgovarajuće tolerancije glukoze, insulinske rezistencije, hiperglikemije, hiperinsulinemije, hiperlipidemije, hipertrigliceridemije, hiperholesterolemije, dislipidemije, gojaznosti, starenja, sindroma X, ateroskleroze, bolesti srca, šloga, hipertenzije i periferne vaksularne bolesti.
10. Jedinjenje za upotrebu prema patentnom zahtevu 8, naznačeno time što navedeni poremećaj želudca je izabran grupe koja se sastoji od postoperativnog ileusa (POI), dijabetičke gastropareze i disfunkcije creva indukovane opioidom.
11. Jedinjenje za upotrebu prema patentnom zahtevu 8, naznačeno time što je navedena gastrointestinalna bolest izabrana iz grupe koja se sastoji od sindroma iritabilnog creva, gastritisa, bolesti refluksa kiseline, gastropareze i funkcionalne dispepsije.
12. Jedinjenje za upotrebu prema patentnom zahtevu 8, naznačeno time što, navedena zloupotreba supstanci je zloupotreba alkohola ili zloupotreba leka/droge.
13. Jedinjenje za upotrebu prema patentnom zahtevu 12, naznačeno time što je navedeni lek/droga izabran iz grupe koja se sastoji od amfetamina, barbiturata, benzodiazepina, kokaina, metakvalona i opioida.
14. Jedinjenje za upotrebu prema bilo kom od patentnih zahteva 8 do 13, naznačeno time što navedeno jedinjenje ili njegova farmaceutski prihvatljiva so ili adukt, je modulator receptora za grelin.
15. Jedinjenje za upotrebu prema bilo kom od patentnih zahteva 8 do 14, naznačeno time što navedeno jedinjenje ili njegova farmaceutski prihvatljiva so ili adukt, je primenjeno preko jednog ili više puteva izabranih iz grupe koja se sastoji od rektalne, bukalne, sublingvalne, intravenske, subkutane, intradermalne, transdermalne, intraperitonealne, oralne, preko kapi za oči, parenteralne i topikalne primene.
16. Jedinjenje za upotrebu prema bilo kom od patentnih zahteva 8 do 15, naznačeno time što navedena primena je postignuta primenom oralnog oblika navedenog jedinjenja ili njegove farmaceutski prihvatljive soli ili adukta.
17. Jedinjenje za upotrebu prema bilo kom od patentnih zahteva 8 do 16, naznačeno time što navedeno jedinjenje ili njegova farmaceutski prihvatljiva so ili adukt, je primenjeno u količini od 0.01 mikrograma po kg (μg/Kg) telesne težine na dan do 100 mg/Kg telesne težine na dan, od 0.1 μg /Kg/dan do 10 mg/Kg/dan, od 1 μg /Kg /dan do 5 mg/ Kg /dan, od 10 μg /Kg/dan do 5 mg/Kg/dan, od 100 μg /Kg/dan do 5 mg/Kg/dan, ili od 500 μg /Kg/dan do 5 mg/Kg/dan.
18. Jedinjenje za upotrebu prema bilo kom od patentnih zahteva 8 do 17, koje dalje sadrži primenu jednog ili više terapeutskih sredstava.
19. Jedinjenje za upotrebu prema bilo kom od patentnih zahteva 8 do 18, naznačeno time što subjekat je čovek.
20. Jedinjenje za upotrebu prema bilo kom od patentnih zahteva 8 do 19, naznačeno time što subjekat je identifikovan tako da mu je potreban tretman bolesti ili primena.
21. Farmaceutska kompozicija za upotrebu u prevenciji i/ili lečenju subjekta koji sadrži terapeutski efikasnu količinu jedinjenja prema bilo kom od patentnih zahteva 1-7, i jedan ili više farmaceutski prihvatljivih ekscipijenasa.
22. Farmaceutska kompozicija koja sadrži terapeutski efikasnu količinu jedinjenja prema bilo kom od patentnih zahteva 1- 7, i farmaceutski prihvatljiv nosač ili vehikulum.
MEP-2017-123A 2011-02-25 2012-02-23 ASIMETRIČNE UREE l NJIHOVE MEDICINSKE UPOTREBE ME02845B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/CN2011/000298 WO2012113103A1 (en) 2011-02-25 2011-02-25 Asymmetric ureas and medical uses thereof
US201161466070P 2011-03-22 2011-03-22
PCT/US2012/026315 WO2012116176A2 (en) 2011-02-25 2012-02-23 Asymmetric ureas and medical uses thereof
EP12749383.1A EP2678017B1 (en) 2011-02-25 2012-02-23 Asymmetric ureas and medical uses thereof

Publications (1)

Publication Number Publication Date
ME02845B true ME02845B (me) 2018-01-20

Family

ID=46719417

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2017-123A ME02845B (me) 2011-02-25 2012-02-23 ASIMETRIČNE UREE l NJIHOVE MEDICINSKE UPOTREBE

Country Status (41)

Country Link
US (3) US8658797B2 (me)
EP (1) EP2678017B1 (me)
JP (1) JP6077468B2 (me)
KR (2) KR20140014186A (me)
CN (2) CN103874492B (me)
AP (1) AP3768A (me)
AR (1) AR085398A1 (me)
AU (1) AU2012220531B2 (me)
BR (1) BR112013021566B1 (me)
CA (1) CA2820767C (me)
CL (1) CL2013002412A1 (me)
CO (1) CO6771450A2 (me)
CY (1) CY1118947T1 (me)
DK (1) DK2678017T3 (me)
DO (1) DOP2013000195A (me)
EA (1) EA027374B1 (me)
EC (1) ECSP13012893A (me)
ES (1) ES2628386T3 (me)
GE (1) GEP20156319B (me)
HR (1) HRP20170997T1 (me)
HU (1) HUE035039T2 (me)
IL (1) IL227941A (me)
LT (1) LT2678017T (me)
MA (1) MA34968B1 (me)
ME (1) ME02845B (me)
MX (1) MX347587B (me)
MY (1) MY164354A (me)
NI (1) NI201300070A (me)
PE (1) PE20141000A1 (me)
PH (1) PH12013501757A1 (me)
PL (1) PL2678017T3 (me)
PT (1) PT2678017T (me)
RS (1) RS56033B1 (me)
SG (1) SG192138A1 (me)
SI (1) SI2678017T1 (me)
SM (1) SMT201700407T1 (me)
TN (1) TN2013000346A1 (me)
TW (1) TWI579273B (me)
UA (1) UA113510C2 (me)
WO (2) WO2012113103A1 (me)
ZA (1) ZA201307071B (me)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012113103A1 (en) * 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Asymmetric ureas and medical uses thereof
CA2896076C (en) 2012-12-21 2022-12-06 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
TWI703130B (zh) * 2014-03-07 2020-09-01 瑞士商赫爾辛保健股份有限公司 對位取代的不對稱脲及其醫療用途
RU2686317C2 (ru) * 2015-04-24 2019-04-25 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Замещенные 1,2,5-триметил- и 2,2,6,6-тетраметил-4-аминопиперидины, обладающие антиишемическим действием
CN108884026B (zh) 2016-03-22 2021-05-25 赫尔森保健股份公司 苯磺酰基不对称尿素及其医学用途
EP3679930A4 (en) 2017-08-07 2021-11-17 Hiroshima University THERAPEUTIC FOR FATTY LIVER DISEASES AND THERAPEUTIC FOR OBESITY
EP3672960A2 (en) 2017-08-21 2020-07-01 Acadia Pharmaceuticals Inc. Compounds, salts thereof and their use for the treatment of diseases
MX2020001757A (es) 2017-08-21 2020-09-07 Acadia Pharm Inc Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
JP7171728B2 (ja) 2017-12-11 2022-11-15 ヘルシン ヘルスケア ソシエテ アノニム （ｒ）－３－（１－（２，３－ジクロロ－４－（ピラジン－２－イル）フェニル）－２，２，２－トリフルオロエチル）－１－メチル－１－（１－メチルピペリジン－４－イル）ウレアのフマル酸塩、その調製方法及び使用
EP3542799A1 (en) 2018-03-22 2019-09-25 Helsinn Healthcare SA New centrally-active ghrelin agonist and medical uses thereof
US20240208923A1 (en) 2021-03-10 2024-06-27 Jnana Therapeutics Inc. Small molecule inhibitors of mammalian slc6a19 function
EP4346820B1 (en) 2021-06-02 2025-03-12 Helsinn Healthcare SA Piperidine urea derivatives for use as inotropic agents
WO2023048762A1 (en) * 2021-09-22 2023-03-30 Duke University Compositions for the treatment of food and chemical addiction and methods of making and using same
WO2024158862A1 (en) * 2023-01-25 2024-08-02 University Of North Texas Health Science Center Thiourea antioxcompounds with neuroprotective activity

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5285174A (en) * 1976-01-05 1977-07-15 Yoshitomi Pharmaceut Ind Ltd Novel urea or thiourea derivatives
WO1995006635A1 (en) 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
AU3785597A (en) 1996-08-14 1998-03-06 Takeda Chemical Industries Ltd. Cyclic urea compounds, their production and use as herbicides
US6399619B1 (en) 1999-04-06 2002-06-04 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
ES2278729T3 (es) * 2000-03-06 2007-08-16 Acadia Pharmaceuticals Inc. Compuestos azaciclicos para usar en el tratamiento de enfermedades relacionadas con la serotonina.
GB0011838D0 (en) * 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
US20030022891A1 (en) * 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
WO2002070479A1 (en) 2001-03-01 2002-09-12 Astrazeneca Ab N-4-piperidinyl compounds as ccr5 modulators
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
US6673829B2 (en) * 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
SE0200919D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Chemical compounds
AU2003268493A1 (en) * 2002-09-11 2004-04-30 Merck & Co., Inc. Piperazine urea derivatives as melanocortin-4 receptor agonists
JPWO2004046110A1 (ja) 2002-11-15 2006-03-16 アステラス製薬株式会社 メラニン凝集ホルモン受容体拮抗剤
JP4384635B2 (ja) * 2003-06-30 2009-12-16 住友化学株式会社 不斉尿素化合物およびこれを触媒として用いる不斉共役付加反応による不斉化合物の製造方法
US7115767B2 (en) * 2003-07-18 2006-10-03 Abbott Laboratories Tetraline derivatives as ghrelin receptor modulators
KR20070001976A (ko) * 2004-02-10 2007-01-04 얀센 파마슈티카 엔.브이. 알파４ 인테그린의 길항제로서의 피리다지논 우레아
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
GB0412865D0 (en) 2004-06-09 2004-07-14 Glaxo Group Ltd Chemical compounds
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
SE0401971D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
CA2577060A1 (en) * 2004-08-13 2006-02-23 Amgen Inc. Substituted benzofused heterocycles
AU2005302669A1 (en) * 2004-10-27 2006-05-11 Neurogen Corporation Diaryl ureas as CB1 antagonists
EP1831194A4 (en) 2004-12-21 2009-12-02 Astrazeneca Ab HETEROCYCLIC ANTAGONISTS OF MCHr1 AND THERAPEUTIC APPLICATIONS THEREOF
US7829589B2 (en) 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
US20080300251A1 (en) * 2005-09-05 2008-12-04 Sattigeri Jitendra A Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors
KR20080076916A (ko) * 2005-11-01 2008-08-20 트랜스테크 파르마, 인크. 치환된 아미드의 약학적 사용
AR058277A1 (es) * 2005-12-09 2008-01-30 Solvay Pharm Gmbh N- sulfamoil - piperidin - amidas, composiciones farmaceuticas que las comprenden y procedimiento para su preparacion
WO2008008286A2 (en) 2006-07-12 2008-01-17 Merck & Co., Inc. Substituted pyrazoles as ghrelin receptor antagonists
JP2008042298A (ja) 2006-08-02 2008-02-21 Olympus Corp 固体撮像装置
GB0701992D0 (en) 2007-02-02 2007-03-14 7Tm Pharma As Grehlin Receptor Modulators
WO2008141057A1 (en) * 2007-05-08 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea
GB0710863D0 (en) * 2007-06-06 2007-07-18 Glaxo Group Ltd Novel compounds
GB0710865D0 (en) 2007-06-06 2007-07-18 Glaxo Group Ltd Novel compounds
WO2009020960A1 (en) 2007-08-06 2009-02-12 The Regents Of The University Of California Preparation of novel 1,3-substituted ureas as inhibitors of soluble epoxide hydrolase
JP2010540454A (ja) * 2007-09-21 2010-12-24 アカディア ファーマシューティカルズ，インコーポレーテッド ピマバンセリンと他の薬剤との併用投与
UA100527C2 (en) * 2007-10-10 2013-01-10 Астразенека Аб Benzothiazoles as ghrelin receptor modulators
WO2009092293A1 (en) 2008-01-18 2009-07-30 Shanghai Targetdrug Co., Ltd. Pyrollidine-based compounds
WO2009089659A1 (en) 2008-01-18 2009-07-23 Shanghai Targetdrug Co., Ltd. Pyrollidine-based compounds
EP2336105B9 (en) * 2008-09-19 2014-09-17 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use of same
WO2010111353A1 (en) * 2009-03-25 2010-09-30 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
WO2011060397A1 (en) * 2009-11-16 2011-05-19 Schering Corporation Substituted amino heterocycles useful as hiv antagonists
WO2012113103A1 (en) * 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Asymmetric ureas and medical uses thereof

Also Published As

Publication number Publication date
CY1118947T1 (el) 2018-01-10
MY164354A (en) 2017-12-15
EP2678017A2 (en) 2014-01-01
IL227941A0 (en) 2013-09-30
CA2820767A1 (en) 2012-08-30
DK2678017T3 (en) 2017-07-24
ES2628386T3 (es) 2017-08-02
MX2013006974A (es) 2013-10-07
US20140121210A1 (en) 2014-05-01
US20120220629A1 (en) 2012-08-30
KR20140014186A (ko) 2014-02-05
PE20141000A1 (es) 2014-08-09
TW201245151A (en) 2012-11-16
CL2013002412A1 (es) 2014-02-07
MX347587B (es) 2017-05-03
WO2012113103A1 (en) 2012-08-30
WO2012116176A2 (en) 2012-08-30
CN106995403B (zh) 2020-04-24
MA34968B1 (fr) 2014-03-01
US8658797B2 (en) 2014-02-25
NI201300070A (es) 2014-03-11
JP2014518543A (ja) 2014-07-31
BR112013021566A2 (pt) 2016-11-08
ECSP13012893A (es) 2013-11-29
EP2678017A4 (en) 2015-05-20
EA201300946A1 (ru) 2014-06-30
ZA201307071B (en) 2014-06-25
US20180044293A1 (en) 2018-02-15
EP2678017B1 (en) 2017-04-05
RS56033B1 (sr) 2017-09-29
CN106995403A (zh) 2017-08-01
KR101907573B1 (ko) 2018-10-15
WO2012116176A3 (en) 2014-04-24
US10407390B2 (en) 2019-09-10
US9751836B2 (en) 2017-09-05
AU2012220531B2 (en) 2017-02-23
AP2013007123A0 (en) 2013-09-30
PT2678017T (pt) 2017-06-26
TN2013000346A1 (en) 2015-01-20
HRP20170997T1 (hr) 2017-10-06
CN103874492B (zh) 2016-12-07
GEP20156319B (en) 2015-07-10
EA027374B1 (ru) 2017-07-31
NZ615283A (en) 2015-09-25
LT2678017T (lt) 2017-06-26
PL2678017T3 (pl) 2017-09-29
TWI579273B (zh) 2017-04-21
KR20180075703A (ko) 2018-07-04
DOP2013000195A (es) 2014-12-15
AU2012220531A1 (en) 2013-09-26
SI2678017T1 (sl) 2017-07-31
JP6077468B2 (ja) 2017-02-08
PH12013501757A1 (en) 2013-10-14
CO6771450A2 (es) 2013-10-15
AP3768A (en) 2016-08-31
AR085398A1 (es) 2013-09-25
CN103874492A (zh) 2014-06-18
CA2820767C (en) 2019-06-25
SMT201700407T1 (it) 2017-09-07
IL227941A (en) 2017-10-31
HUE035039T2 (en) 2018-05-02
UA113510C2 (uk) 2017-02-10
BR112013021566B1 (pt) 2020-11-17
SG192138A1 (en) 2013-08-30

Similar Documents

Publication Publication Date Title
ME02845B (me) ASIMETRIČNE UREE l NJIHOVE MEDICINSKE UPOTREBE
US20240352031A1 (en) Thieno[2,3-D]pyrimidin-4-one Derivatives as NMDAR Modulators and Uses Related Thereto
CN100409845C (zh) Cb1受体拮抗剂与西布茶明的组合形式、其药物组合物及其在制备治疗肥胖病的药物中的应用
JP6440321B2 (ja) スルホンアミド誘導体またはその薬学的に許容される酸付加塩
JP2009538873A5 (me)
US20100168174A1 (en) Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain
RU2007107189A (ru) Производные арилпиридина
JP2002080453A5 (me)
JP2004528334A5 (me)
JPWO2020014246A5 (me)
RU2001114978A (ru) N-ариламиды антраниловой кислоты и тиоантраниловой кислоты
RU2003134544A (ru) Амиды антраниловой кислоты, способы их получения, их применение в качестве антиаритмических средств, а также содержащие их фармацевтические композиции
CA2376305A1 (en) Sulfonamide and sulfamide substituted imidazoquinolines
CA2748400A1 (en) Combinations comprising methotrexate and dhodh inhibitors
JP2010535824A (ja) Ｄｈｏｄｈ阻害剤としてのアザビフェニルアミノ安息香酸誘導体
JP2009542702A5 (me)
TW200412970A (en) Pharmaceutical composition comprising PDE 5 inhibitor and active ingredients
JP2013532668A5 (me)
JP2007519753A5 (me)
RU2003103780A (ru) Соединения фенилпиридазина и содержащие их лекарственные средства
CA2504907A1 (en) Indoles useful in the treatment of androgen-receptor related diseases
RU2004107854A (ru) Производные 4[пиперидин-4-илиден-(3-карбомоилфенил)метил]бензамида и их применение для лечении боли, спинальных повреждений или желудочно-кишечных расстройств
JP2010522218A5 (me)
CN1511036B (zh) 包含信号转导抑制剂和埃坡霉素衍生物的联合形式
JP2005505583A5 (me)